ABT-100

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ABT-100  纯度: 98.18%

ABT-100 是一种有效的，高选择性和口服活性的 farnesyltransferase 抑制剂。ABT-100 抑制细胞增殖 (对于 EJ-1，DLD-1，MDA-MB-231，HCT-116，MiaPaCa-2，PC-3 和 DU-145 细胞的 IC50 分别为 2.2 nM，3.8 nM，5.9 nM，6.9 nM，9.2 nM，70 nM 和 818 nM)，可增加细胞凋亡并减少血管生成。ABT-100 具有广谱抗肿瘤活性。

ABT-100

ABT-100 Chemical Structure

CAS No. : 450839-40-4

规格 价格 是否有货 数量
5 mg ￥4000 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

ABT-100 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Chemical Probe Library
  • Anti-Pancreatic Cancer Compound Library

生物活性

ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity[1].

IC50 & Target

Farnesyltransferase[1]
体外研究
(In Vitro)

ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. Also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells
Concentration: 0.1-100 nM
Incubation Time: 7 days
Result: Demonstrated dose-dependent growth inhibition of human cancer cell lines.

体内研究
(In Vivo)

ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C.B-17 scid male mice with EJ-1 cells[1]
Dosage: 6.25 mg/kg/day, 12.5 mg/kg/day
Administration: Subcutaneous injection; daily; for 21 days
Result: Regressed EJ-1 tumors in C.B-17 scid male mice.

分子量

504.46

Formula

C27H19F3N4O3
CAS 号

450839-40-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (99.12 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9823 mL 9.9116 mL 19.8232 mL
5 mM 0.3965 mL 1.9823 mL 3.9646 mL
10 mM 0.1982 mL 0.9912 mL 1.9823 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Ferguson D, et al. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res. 2005 Apr 15;11(8):3045-54.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务